← Back to Search

BAY 94-9172 (Florbetaben) for Alzheimer's Disease

N/A

Waitlist Available

Led By Richard Mayeux, BS, MD, MSc

Research Sponsored by New York State Psychiatric Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up amyloid plaque load in the brain will be measured at baseline and again 3 years later

Awards & highlights

Study Summary

This trial is investigating whether biomarkers in the blood can be used to predict risk and progression of Alzheimer's disease. They will also look at whether increased levels of amyloid beta in the brain, as measured by positron emission tomography (PET) imaging, are associated with cognitive decline.

Eligible Conditions

Alzheimer's Disease

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ amyloid plaque load in the brain will be measured at baseline and again 3 years later

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~amyloid plaque load in the brain will be measured at baseline and again 3 years later

This trial's timeline: 3 weeks for screening, Varies for treatment, and amyloid plaque load in the brain will be measured at baseline and again 3 years later for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Changes in amyloid plaque load in the brain of the course of 3 years

Trial Design

1Treatment groups

Experimental Treatment

Group I: BAY 94-9172Experimental Treatment1 Intervention

BAY 94-9172 PET/CT

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

BAY 94-9172 (Florbetaben)

2010

N/A

~170

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

BayerIndustry Sponsor

2,237 Previous Clinical Trials

25,326,817 Total Patients Enrolled

National Institute on Aging (NIA)NIH

1,668 Previous Clinical Trials

28,004,903 Total Patients Enrolled

New York State Psychiatric InstituteLead Sponsor

475 Previous Clinical Trials

153,746 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has there ever been a similar research trial conducted prior to this one?

"Currently, 7 live clinical trials for BAY 94-9172 (Florbetaben) are being held across 2 nations and 3 cities. This therapeutic agent was first assessed in 2010 through a Bayer sponsored trial with an enrolment of 161 individuals that completed its drug approval stage. In the past decade since then, 12 more studies have been conducted."

Answered by AI

Are there vacancies for individuals to join this research?

"Per the clinicaltrials.gov database, this medical trial is not currently accepting new patients. This particular study was initially posted on December 1st 2010 and its last update occurred February 11th 2022. In spite of this inactivity, there are still 555 other experiments that require recruitment at present time."

Answered by AI

Are there any historical precedents of trials with BAY 94-9172 (Florbetaben)?

"Presently, seven clinical trials are being conducted to assess the efficacy of BAY 94-9172 (Florbetaben). All these studies are in preclinical stages. The majority of research is occurring at Philadelphia, Pennsylvania but there exist 9 other sites running tests on this medication."

Answered by AI

How many participants is the trial recruiting?

"This study has ceased its recruitment efforts; it was last updated on February 11th 2022. If you are seeking other trials, 548 studies for Alzheimer's disease and 7 investigations involving BAY 94-9172 (Florbetaben) are currently recruiting patients."

Answered by AI

Recent research and studies

Archives of NeurologyJournal

Plasma Β-amyloid and Cognitive Decline

Cosentino, Stephanie A., Yaakov Stern, Elisaveta Sokolov, Nikolaos Scarmeas, Jennifer J. Manly, Ming Xin Tang, Nicole Schupf, and Richard P. Mayeux. 2010. “Plasma Β-amyloid and Cognitive Decline”. Archives of Neurology. American Medical Association (AMA). doi:10.1001/archneurol.2010.189.

Current Alzheimer ResearchJournal

High PIB Retention in Alzheimers Disease Is an Early Event with Complex Relationship with CSF Biomarkers and Functional Parameters

Forsberg, A., O. Almkvist, H. Engler, A. Wall, B. Langstrom, and A. Nordberg. 2010. “High PIB Retention in Alzheimers Disease Is an Early Event with Complex Relationship with CSF Biomarkers and Functional Parameters”. Current Alzheimer Research. Bentham Science Publishers Ltd.. doi:10.2174/156720510790274446.

Plos OneJournal

Brain Amyloid Deposition and Longitudinal Cognitive Decline in Nondemented Older Subjects: Results from a Multi-ethnic Population

Gu, Yian, Qolamreza R. Razlighi, Laura B. Zahodne, Sarah C. Janicki, Masanori Ichise, Jennifer J. Manly, D. P. Devanand, et al.. 2015. “Brain Amyloid Deposition and Longitudinal Cognitive Decline in Nondemented Older Subjects: Results from a Multi-ethnic Population”. Edited by Paul B. Rosenberg. Plos One. Public Library of Science (PLoS). doi:10.1371/journal.pone.0123743.

clinicaltrials.govStudy